Proteomics International Laboratories

PIQ.AX

Medical - Care Facilities · Healthcare

Exchange

Australian Securities Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Proteomics International Laboratories Ltd. is an Australian biotech company that studies proteins in the human body to develop medical tests and treatments. Its main focus is a diagnostic test called PromarkerD, which is designed to predict the risk of kidney disease in people with diabetes. The company sells its services to research institutions, pharmaceutical companies, and healthcare providers.

The company earns revenue through laboratory testing services and licensing agreements, though it is still in an early commercial stage and currently spends far more than it earns, as reflected in its deeply negative margins. It operates primarily in Australia but is working to expand PromarkerD into international markets, including the United States and Europe. Its main competitive edge is its proprietary protein-analysis technology and patents around PromarkerD, but the biggest risk it faces is achieving enough commercial adoption of its diagnostic test to reach profitability before needing to raise additional capital.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-95.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-47.3% YoY

YoY Growth Rate

Earnings declining

Insider Activity

24.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~6 months

A$11M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Proteomics International Laboratories has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-1399.7%

Thin — -1399.7% gross margin

Profit after running costs

Operating Margin

-1828.3%

Losing money on operations — -1828.3%

Return on the money invested

ROCE

-155.4%

Weak — -155.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-86.3%

Shrinking sales (-86.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-1751.4%

Burning cash (-1751.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.06

Conservative — low debt load (0.06)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial